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Acquired aplastic anemia (AA) is caused by autoreactive T cell–mediated destruction of early
hematopoietic cells. Somatic loss of human leukocyte antigen (HLA) class I alleles was identified as
a mechanism of immune escape in surviving hematopoietic cells of some patients with AA. However,
pathogenicity, structural characteristics, and clinical impact of specific HLA alleles in AA remain
poorly understood. Here, we evaluated somatic HLA loss in 505 patients with AA from 2 multiinstitutional cohorts. Using a combination of HLA mutation frequencies, peptide-binding structures,
and association with AA in an independent cohort of 6,323 patients from the National Marrow
Donor Program, we identified 19 AA risk alleles and 12 non-risk alleles and established a potentially
novel AA HLA pathogenicity stratification. Our results define pathogenicity for the majority of
common HLA-A/B alleles across diverse populations. Our study demonstrates that HLA alleles
confer different risks of developing AA, but once AA develops, specific alleles are not associated
with response to immunosuppression or transplant outcomes. However, higher pathogenicity alleles,
particularly HLA-B*14:02, are associated with higher rates of clonal evolution in adult patients with
AA. Our study provides insights into the immune pathogenesis of AA, opening the door to future
autoantigen identification and improved understanding of clonal evolution in AA.
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Introduction
Acquired aplastic anemia (AA) is an autoimmune bone marrow failure disorder caused by T lymphocyte–
mediated attack on hematopoietic stem and progenitor cells (HSPCs) (1). Antigenic target(s) of the autoimmune attack remain unknown, and triggers and specific mechanisms of autoimmunity in AA remain
poorly understood. Most patients with AA treated with immunosuppressive therapy (IST) develop clonal
hematopoiesis, with somatic mutations in surviving hematopoietic cells (2–6). Among the most commonly
mutated genes in patients with AA are the human leukocyte antigen (HLA) class I genes.
In 2011, Katagiri et al. reported acquired copy number–neutral loss of heterozygosity of chromosome arm 6p (6pCN-LOH) involving the major histocompatibility complex region as a recurrent abnormality in AA and were the first to propose that 6pCN-LOH clones in AA arise due to hematopoietic
cells escaping autoimmune attack through HLA class I allele loss (7). The subsequent discovery of
inactivating somatic mutations in specific HLA class I alleles unambiguously identified HLA class I gene
inactivation as a key mechanism of clonal evolution in AA that is distinct and noncooperative with
genetic mutations and cytogenetic abnormalities that drive transformation to myelodysplastic syndrome
(MDS) (2, 4, 8–11). Somatic inactivation of HLA alleles without any other mutations was sufficient
for clonal expansion in AA, indicating that it was the loss of targeted alleles that created the survival
advantage of HLA allele–lacking hematopoietic cells (10, 12–14). The targeted alleles have been presumed to be responsible for AA autoantigen presentation in the affected patients; henceforth these will
be referred to as “risk alleles.” Next-generation sequencing (NGS) studies of somatic HLA mutations in
AA identified several such HLA class I risk alleles, most notably HLA-B*14:02 and HLA-B*40:02, which
were also significantly enriched in patients with AA (7, 9–11, 15, 16).
However, despite progress, many questions fundamental for our understanding of the role of HLA
class I antigen presentation in AA remain. What determines whether a given HLA allele is able to
mediate autoantigen presentation in AA, and are there alleles that cannot? Do AA risk alleles share
peptide-binding motifs, and could these be used to infer the properties of AA autoantigen(s)? Given the
tremendous diversity of HLA alleles across racial and ethnic groups, is AA in patients of different ethnicities mediated through the same alleles and autoantigen(s)? Finally, while there has been a growing
body of literature on the clinical predictive value of having somatic clones with HLA allele loss (7, 11,
15–19), the significance of the patients’ HLA class I repertoire for development of AA and the impact
that specific risk alleles have on the patients’ clinical course still remain poorly understood.
In our previous bi-institutional study, we found that the presence of 4 AA HLA risk alleles, particularly
HLA-B*14:02, was associated with a higher risk of clonal evolution (10), a finding subsequently confirmed
in a larger NIH cohort (15). Our previous study had insufficient patient numbers to systematically evaluate
the structural characteristics and clinical significance of HLA alleles in AA. We now present a comprehensive analysis of the significance of HLA class I alleles in AA pathogenesis. Here, we analyzed 505 patients
with AA from 2 diverse multi-institutional cohorts (North American Pediatric Aplastic Anemia Consortium, NAPAAC; and Center for International Blood and Marrow Transplant Research, CIBMTR) for
HLA loss, identifying 19 distinct AA HLA risk alleles and 12 non-risk (protective) alleles. Comparison of
HLA allele mutation frequencies, protein structures, and association with AA in an independent cohort of
6,323 patients from the National Marrow Donor Program (NMDP) allowed us to stratify the full spectrum
of pathogenicity of HLA alleles. We then defined the impact of higher pathogenicity alleles (HPA) on outcomes of patients treated with IST and on immunologic complications and outcomes of patients receiving
allogeneic hematopoietic stem cell transplant (alloHSCT).

Results
Somatic HLA loss in patients with AA. We used a combination of targeted NGS of HLA class I genes and
single nucleotide polymorphism array (SNP-A) genotyping in 505 AA patients from 2 multi-institutional consortia, NAPAAC (n = 156 patients) and CIBMTR-discovery (n = 349 patients) (Figure 1 and Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.163040DS1).
Somatic HLA loss was present in 18.6% (29 of 156) of NAPAAC patients, including 11.5% (18 of
156) with 6pCN-LOH and 12.2% (19 of 156) with HLA mutations, of whom 5.1% (8 of 156) of NAPAAC
patients carried both alterations (Figure 2A). Because the CIBMTR-discovery cohort excluded patients with
the 2 most commonly mutated HLA risk alleles, HLA-B*14:02 and HLA-B*40:02, to increase the likelihood
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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of identifying less common risk alleles present in underrepresented racial and ethnic groups, CIBMTR-discovery patients had a lower rate of somatic HLA loss of 12.3% (43 of 349). A total of 30 of 349 CIBMTR-discovery patients (8.6%) had 6pCN-LOH, and 24 of 335 evaluable patients (7.2%) had HLA mutations,
of whom 3.3% (11 of 335 evaluable patients) carried both alterations. Patients with somatic alterations had
a median of 1 HLA-mutant clone each (range 1–7, with one to four 6pCN-LOH clones and 1 to 5 HLA
mutations) (Supplemental Table 2) and did not differ in age (median 15.7 vs. 17.6 years) or prevalence of
paroxysmal nocturnal hemoglobinuria (PNH) clones (both 25.1%) from patients without HLA loss.
We identified 86 somatic mutations targeting HLA-A and HLA-B in 43 patients; there were no mutations in HLA-C (Supplemental Table 2). A total of 44 mutations involved hotspot residues (Figure 2B);
37 involved the previously reported mutation hotspot in HLA-A/B exon 1 (10, 15, 16) (c.19C>T, p.R7*
in 30 patients and c.16delC, p.R7fs in 7 patients); 5 altered the start codon (c.1A>G/T, p.M1?) in alleles
lacking an alternative start at position 4 (Supplemental Figure 1); and 2 changed a highly conserved residue (c.421G>A, p.A141T).
Of the mutations, 81% (70 of 86) were predicted to cause loss of HLA expression through a premature stop or frameshift, splice, or start codon mutations. A total of 15 (17%) were missense mutations,
and 1 was an in-frame deletion (Figure 2C). Of these, 2 altered conserved residues in signal peptide
(Supplemental Figure 1) and were predicted to disrupt HLA trafficking, and 7 altered alpha-3 domain
involved in binding CD8 (20). A total of 7 mutations targeted alpha-1 and alpha-2 domains forming
the peptide-binding pocket: of these, 1 was an 8–amino acid deletion predicted to severely disrupt HLA
structure, 4 (A141T on 2 alleles, Y137D, and H117Q) abrogated surface HLA expression, another
(Y109N) significantly reduced HLA expression, and 1 (Q168H) preserved partial HLA expression with
the potential to alter peptide binding (Figure 2D).
A total of 19 AA HLA risk alleles belong to 6 HLA supertypes. Somatic mutations targeted 18 distinct
HLA class I risk alleles (Figure 3). In patients who had more than 1 clonally expanded population with
somatic HLA loss, all alterations (somatic mutations and 6pCN-LOH) led to the loss of the same HLA
allele, supporting the hypothesis that in each affected patient, a single targeted risk allele was mediating
autoantigen presentation and was responsible for the autoimmune attack. Of 29 patients with 6pCNLOH but no mutations, we were able to unambiguously determine the deleted HLA haplotype in 23
(Supplemental Table 2). In 16 of these 23 patients, the deleted haplotype contained at least 1 known
risk allele. In 1 patient, the involved region included only the HLA-A locus, allowing us to identify 1
additional risk allele (HLA-A*02:06), thus bringing the total identified risk alleles to 19. Approximately
90% of the discovery cohort patients carried 1 or more of the 19 identified risk alleles: 34.7% had 1,
41% — 2, 10.7% — 3, and 1.2% — 4 risk alleles.
Sixteen of the 19 identified AA HLA risk alleles belonged to 6 structurally related groups with shared
peptide-binding specificities called HLA supertypes (21): B44 (n = 4 alleles), B27 (n = 3), A03 (n = 3), B07
(n = 3), A02 (n = 2), and B08 (n = 1) (Figure 4). Of 3 risk alleles with no assigned supertype, HLA-B*38:02
had features of B27 and HLA-B*49:01 of B44 supertype (21).
HLA allele pathogenicity stratification rating. We reasoned that because the selective pressure on HSPCs
to lose HLA alleles may reflect the role these alleles play in mediating autoimmune attack in patients
with AA, the prevalence of somatic allele loss may indicate how frequently a given allele is responsible
for autoimmune recognition in AA. We thus systematically compared mutation frequencies for 161
distinct HLA class I alleles (45 HLA-A, 75 HLA-B, and 40 HLA-C) in the discovery cohort. Individual
alleles were present in a median of 4 patients (range 1 to 193), with 37 alleles (11 HLA-A, 14 HLA-B, and
12 HLA-C) present in at least 20 patients.
Prevalence of mutations in patients carrying a given allele ranged from 36% (9 of 25 allele-carrying
patients) for HLA-B*14:02 to 1.7% (2 of 119) for HLA-B*07:02 (P < 0.001) (Figures 4 and 5). Alleles from
B27 supertype were mutated significantly more frequently (12%, 14 of 114 allele-carrying patients) than
alleles from other supertypes (B08 supertype — 4.3%, B44 — 3.6%, A02 — 2.1%, A03 — 2.0%, B07 —
1.3%, and 0% for A01, A01A03, A01A24, A24, B58, or B62 supertypes; P < 0.05). HLA alleles were
targeted by mutations at significantly different frequencies, allowing us to cluster the alleles into 5 different
pathogenicity risk groups, defined by differences in mutation frequency: high (>15%), high-intermediate
(>5%–15%), low-intermediate (>3%–5%), low (≤3%), and non-risk (0%) (Figure 5).
High-risk alleles (HLA-B*14:02, HLA-B*14:01, HLA-B*40:02, HLA-A*33:03, HLA-B*49:01, and HLA-B*41:02)
were mutated in 16.7% to 36% of high-risk allele carriers, with a significantly higher mutation frequency than
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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Figure 1. Flowchart summarizing patient cohorts and methods used in this study. The flowchart summarizes the study
progression and lists the patient cohorts that were used for each analysis. (A) The analysis of somatic HLA loss and discovery of HLA risk alleles were performed in the 505-patient discovery cohort, which was composed of 156 patients from North
American Pediatric Aplastic Anemia Consortium (NAPAAC cohort) and 349 patients enrolled in the Center of International
Blood and Marrow Transplant Research (CIBMTR-discovery cohort). HLA mutation data generated from the discovery cohort
were used for HLA pathogenicity stratification, which led to the identification of HLA risk and non-risk alleles. (B) HLA risk
and non-risk alleles identified by studies in A were then evaluated for association with AA using an independent cohort of
6,323 patients with AA and 230,965 matched controls enrolled in the National Marrow Donor Program (NMDP). (C) Analysis
of clinical outcomes following immunosuppressive therapy (IST) was performed in the 156-patient NAPAAC cohort, which
included both pediatric and adult patients. (D) Analysis of clinical outcomes following allogeneic hematopoietic stem cell
transplant (alloHSCT) was performed in an independent cohort (CIBMTR-outcomes cohort) of 484 AA patients who received
matched related or unrelated donor (MRD/MUD) alloHSCT and were enrolled in the CIBMTR. Outcomes of haploidentical
transplant were evaluated in a separate cohort of 29 patients with AA who underwent haploidentical transplant (CIBMTR-haplo). GVHD, graft-versus-host disease; SAA, severe aplastic anemia.

low-risk alleles (HLA-B*18:01, HLA-A*02:01, and HLA-B*07:02), which were mutated in only 1.7% to 2.7%
of allele carriers. High-intermediate alleles (HLA-B*56:01, HLA-A*74:01, HLA-B*27:05, and HLA-B*13:02)
were mutated in 7.1% to 14.3% of carriers, while low-intermediate alleles (HLA-B*53:01, HLA-B*08:01, and
HLA-A*68:01) were mutated in 4.0% to 4.5% of allele carriers. A total of 8 very common alleles (HLA-A*01:01,
HLA-A*03:01, HLA-A*24:02, HLA-B*44:02, and HLA-C alleles HLA-C*04:01, HLA-C*06:02, HLA-C*07:01,
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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Figure 2. Somatic HLA loss in patients with AA. (A) Bar chart showing the frequency of somatic HLA loss in patients with AA in the discovery cohort (CIBMTR-discovery and NAPAAC). Somatic HLA loss was detected as somatic mutations (red and purple bars) and/or acquired 6pCN-LOH (purple and blue bars) in
18.6% of NAPAAC cohort and 12.3% of CIBMTR-discovery cohort. (B) A schematic showing 86 somatic HLA mutations identified in the discovery cohort.

JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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The domains of HLA molecules include signal peptide (SP), the alpha-1 and alpha-2 domains forming the HLA peptide-binding pocket, and alpha-3 and
transmembrane (TM) domains. Loss-of-function mutations due to loss of start (p.M1?), frameshift (fs), splice site (p.? splice), and nonsense variants (*) are
shown in blue above the respective genes. Missense and in-frame deletion variants are shown in red below. The numbers refer to the amino acids in the full
HLA protein. (C) A pie chart showing the breakdown of identified somatic HLA mutations by type. (D) Representative flow histograms showing surface HLA
expression of mutant HLA alleles. Mutant (red and green) and wild-type (WT, blue) alleles were transfected into cell lines lacking endogenous HLA expression (untransfected, shown in dark gray). n = 3–4 replicates per allele, as shown. On the right is the summary analysis showing mean ± standard deviation
for percentage of surface HLA expression normalized to the corresponding WT alleles. *P < 0.05, ****P < 0.0001, using ordinary 1-way ANOVA (nonparametric or mixed) in GraphPad Prism.

HLA-C*07:02), none of which were mutated in our cohort, were statistically significantly less likely to be mutated than high and high-intermediate risk alleles; these were classified as non-risk (Figure 5). Twenty additional
alleles without mutations were analyzed in 20 or more patients, providing sufficient statistical power to conclude that their pathogenicity is at most low risk; these are listed as low or non-risk in Supplemental Figure 3.
High-risk alleles had an average of 2.4 mutations/patient (range 1–4) while low-risk alleles had an average of 1
mutation/patient (range 1–1.6) (Figure 5).
A total of 38 patients in the discovery cohort carried 2 or more risk alleles and had HLA mutations,
allowing us to infer the single risk allele mediating autoimmune recognition in each patient. Consistent
with their pathogenicity rating, high-risk alleles were inferred to mediate autoimmune recognition in 92.3%
of patients (12 of 13), high-intermediate in 83.3% of patients, and low-intermediate in 38.5% of patients
(Supplemental Table 3). In contrast, low-risk alleles were nearly always uninvolved and were inferred to
mediate autoimmune recognition in only 8.7% (2 of 23) of patients.
Structural characteristics of AA risk and non-risk HLA alleles. The repertoire of peptides capable of binding
to an HLA molecule is determined by critical amino acids that comprise the HLA peptide–binding groove
and make contact with the anchor residues of the peptide (22) (Figure 6A). To define structural elements
of AA HLA risk alleles, we aligned previously defined critical residues of the HLA-binding pockets (22) in
AA risk and non-risk alleles.
Strikingly, several risk alleles had identical or nearly identical peptide-binding pocket structural motifs
(PPSMs), indicating that they likely bind the same (or highly similar) AA autoantigen(s) (Figure 6B). We identified 4 distinct risk PPSMs: risk-PPSM1 shared by HLA-B*14:02 and HLA-B*14:01; risk-PPSM2 by HLA-B*40:02
and HLA-B*41:02; risk-PPSM3 by HLA-B*56:01 and 2 previously reported risk alleles, HLA-B*55:02 and
HLA-B*54:01 (13, 16); and risk-PPSM4 by HLA-A*02:01, HLA-A*02:06, and a previously reported risk allele,
HLA-A*02:05 (15). Alleles with shared PPSMs had similar AA pathogenicity (e.g., risk-PPSM1 and riskPPSM2 allele pairs are high-risk, Figure 5).
Non-risk alleles also formed groups with distinct pocket residues, suggesting that certain peptide-binding structures are less suitable to binding AA autoantigens. Four non-risk (NR) PPSMs were identified:
NR-PPSM1 shared by HLA-A*03:01 and HLA-A*11:01; NR-PPSM2 by HLA-A*24:02 and HLA-A*23:01 (a
less common allele in discovery cohort with no mutations in 11 analyzed patients), and NR-PPSM3 by
HLA-B*44:02 and HLA-B*44:03 (Figure 6C), bringing the number of non-risk alleles to 7.
The identified peptide-binding pocket structures corresponded to distinct peptide repertoires, which
can be represented by peptide motifs (peptide anchor residues necessary for binding a given allele) (Figure 6, D and E). Using experimentally determined peptidome data available for 16 risk alleles (23), we
identified 5 distinct peptide motifs, likely corresponding to distinct AA autopeptides originating from a
larger shared protein (or similar proteins) (Figure 6D). As expected, peptide repertoires of risk alleles
differed from those of non-risk alleles (Figure 6E).
HLA risk alleles predispose to AA while non-risk alleles do not mediate AA. To test the hypothesis that HLA
risk alleles may predispose to AA at higher rates than non-risk alleles, we performed an association analysis
in 6,323 patients with AA (3,979 White, 1,030 Black, 841 Hispanic, 463 Asian and Pacific Islander, and 40
Native American) and 230,965 NMDP healthy donor controls, matched for racial and ethnic group (31,057
to 50,000 per ethnic group, based on availability, detailed in Figure 7 and Supplemental Table 4).
After adjusting for the FDR due to multiple allele testing (24), 6 risk alleles (HLA-A*02:01, HLA-A*02:06,
HLA-B*07:02, HLA-B*08:01, HLA-B*14:02, and HLA-B*40:02) were significantly overrepresented in patients
with AA compared with controls in at least 1 racial or ethnic group (Padjusted FDR < 0.05) (Figure 7A and Supplemental Table 5, A–E). To explore potential associations with rare HLA alleles and to evaluate for HLA
associations in less well represented racial and ethnic groups, we also reviewed the raw analysis without FDR
adjustment, as has been done in all previous AA HLA association studies (7, 10, 15, 25–28). Using unadjusted
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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Figure 3. The number of clones with HLA loss identified in the discovery cohort for 19 HLA risk alleles. Risk alleles are listed along the y axis. Mutations
(red bars) and 6pCN-LOH events (blue bars) for NAPAAC cohort are shown on the left and CIBMTR (discovery) on the right.

analysis, 10 of 19 identified AA HLA risk alleles were significantly enriched in AA (Figure 7B). The association with AA was strongest for high-risk alleles, with ORs for significant associations ranging in different ethnic
groups from 1.35 to 2.15 for HLA-B*14:01, 1.83 to 2.17 for HLA-B*14:02, and 1.77 to 2.70 for HLA-B*40:02,
while low-risk alleles had OR 1.25 for HLA-A*02:01 and 1.19 to 1.29 for HLA-B*07:02 (Figure 7A and Supplemental Table 5, A–E, for ORs with 95% CIs for each allele in different ethnicities).
In contrast to risk alleles, 5 of 7 non-risk alleles (HLA-A*01:01, HLA-A*03:01, HLA-A*23:01,
HLA-A*24:02, HLA-B*44:03) were significantly underrepresented in AA in at least 1 ethnic group, consistent with their protective role in AA (Figure 7 and Supplemental Table 5). Of these, HLA-A*03:01 and
HLA-B*44:03 were protective in multiple ethnicities with approximately 20% to 30% (OR range 0.69–0.79)
and approximately 45% to 55% (OR range 0.45–0.63) AA risk reduction, respectively.
Association analysis further clarified the pathogenicity of 10 HLA-A/B alleles, which we estimated as
being either low-risk or non-risk based on lack of HLA mutations in the discovery cohort (Supplemental Figure
3, and Supplemental Table 6, A–E). Five alleles (HLA-A*26:01, HLA-A *29:02, HLA-B*15:01, HLA-B*25:01,
HLA-B*57:01) were negatively associated with AA, of which HLA-A*26:01, HLA-A*29:02, and HLA-B*57:01
were 20% to 30% protective in several ethnicities — these 5 alleles were reclassified as non-risk. In contrast,
HLA-A*32:01 was enriched in White (OR 1.15), and HLA-B*40:01 in Asian (OR 1.36), patients. Rare mutations in HLA-B*40:01 were previously reported, consistent with it being a low-risk allele (15, 16).
Population-based drivers of AA. We determined AA pathogenicity for the common HLA-A and HLA-B
alleles accounting for approximately 85% of White, 75% Native American, 71% Hispanic, 62% Asian,
and 60% Black NMDP populations. The remaining HLA-A and HLA-B alleles (~15% alleles in White to
38%–40% in Asian and Black NMDP populations) were rare and insufficiently represented in the discovery
cohort to assess pathogenicity. When analyzed as a group, the remaining HLA-A alleles were negatively
associated with AA in Native American and White people, and the remaining HLA-B alleles were negatively associated with AA in Black, Hispanic, and White populations, indicating that the majority of AA
risk carried by HLA class I alleles in Black, Hispanic, Native American, and White populations was captured by analysis of our diverse discovery cohort (Supplemental Table 7).
A comparison of AA risk allele associations across racial and ethnic groups demonstrated a contribution to AA risk from a common set of alleles (HLA-A*02:01, HLA-B*07:02, HLA-B*08:01, HLA-B*14:01,
HLA-B*14:02, and HLA-B*40:02) (Figure 8 and Figure 9) but also identified alleles contributing disproportionately in specific populations. In Asian patients, AA was primarily driven by HLA-B*40:02, with strong contributions from HLA-A*02:06, HLA-A*74:01, and HLA-B*53:01, but virtually no contribution from HLA-B*14:02.
Black patients had higher contributions from HLA-B*14:01 and HLA-B*49:01, and HLA-B*50:02, but virtually
no contribution from HLA-B*40:02. Contributions to AA were similar in the White and Hispanic AA populations, but HLA-A*02:06, HLA-A*33:03, HLA-B*50:02, and HLA-B*53:01 contributed more in Hispanic patients.
HPA may predispose to MDS-associated clonal evolution in adult-onset AA. In our 2017 study of HLA risk
alleles in 66 patients with AA, we reported a more complicated disease course with higher rates of MDS (10).
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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Figure 4. Frequency of mutations per allele. Alleles are grouped by HLA supertype, with combined mutation frequency for each supertype shown in
yellow bars. Mutation frequency is shown as blue bars above and mutations per patient as red bars below x axis. *HLA-B*50:02 was analyzed in a single
patient, and mutation frequency could not be determined. Alleles with at least 20 analyzed patients without mutations are shown by green dots.

We now added 90 new patients to more than double our previous cohort and used this expanded (NAPAAC)
cohort to determine the impact of HLA risk alleles on clinical outcomes of patients treated with IST. Of 156
patients, 121 had pediatric-onset AA and 23 adult-onset AA; for another 12 patients, age at AA onset was
unknown (Supplemental Tables 8 and 9). Among patients, 85.2% had severe or very severe AA, and 78.5%
of the cohort received frontline IST with antithymocyte globulin and cyclosporine. Median duration of follow-up, censored for transplantation, was 5.6 years.
Because all patients with AA patients have HLA class I alleles mediating autoimmune recognition, albeit
of varying pathogenicities, we focused on the role of HPA, stringently defined as high- or high-intermediate
risk alleles (Figure 5 and Supplemental Methods). Nine alleles (HLA-A*33:03, HLA-B*13:02, HLA-B*14:01,
HLA-B*14:02, HLA-B*27:05, HLA-B*40:02, HLA-B*41:02, HLA-B*49:01, HLA-B*56:01) were categorized as
HPA. Patients without HPA were analyzed in the group with lower pathogenicity alleles (LPA).
Patients with HPA (n = 62) did not differ from patients with LPA (n = 94) in age at AA onset, severity,
marrow cellularity, responses to IST at 6 months, risk of relapse, second-line therapies, death, or duration
of follow-up (Supplemental Tables 8 and 9). However, in agreement with our earlier findings (10), patients
with HPA were more likely to develop MDS (10.2% vs. 1.4%, OR 8.07, P = 0.039), had more 6pCNLOH clones (19.4% vs. 6.4%, OR 3.52, P = 0.020), and had a non–statistically robust trend toward more
cytogenetic abnormalities (15.9% vs. 4.8%, OR 3.67, P = 0.089) (Table 1 and Table 2). Of 6 patients who
developed post-AA MDS, 5 had HPA.
The effect of HPA on clonal evolution depended on age of AA onset. Pediatric-onset patients with
HPA developed 6pCN-LOH clones at higher rates than those with LPA (21.3% vs. 6.8% OR 3.73, P =
0.024). In contrast, rates of MDS-associated mutations, cytogenetic abnormalities, or MDS transformation did not significantly differ in pediatric-onset patients by presence or absence of HPA (although the
power to detect differences was limited by low rate of MDS-associated clonal evolution in pediatric-onset
AA, ref. 29). In contrast, adult-onset patients with HPA were significantly more likely to develop karyotypic abnormalities (50% vs. 0%, OR 19, P = 0.033) than adult-onset patients with LPA and had a non–
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Figure 5. Pathogenicity stratification of 18 HLA class I risk alleles with identified somatic mutations and other alleles analyzed in at least 20 patients.
Shown is a pairwise comparison matrix of relative mutation frequencies per individual HLA alleles HLA alleles are listed along the x axis, grouped by
pathogenicity ranking. High-risk, high-intermediate, low-intermediate, and low-risk alleles are shown in decreasing intensity of red and non-risk alleles
in green. B*38:02 and B*50:02 were insufficiently prevalent in the cohort for analysis — these were listed as indeterminate. The number of patient cases
with mutations, total patients with listed allele, percentage mutation frequency, and median number of mutations per patient are listed in the header
rows below each allele. Pairwise comparison of mutation frequencies is shown as a correlation matrix. Comparisons were performed by Fisher’s exact
tests, with P value listed for each pair of alleles. P values < 0.05 are shaded in dark red for comparison OR > 1 or dark green for OR < 1. Trends with P ≥
0.05 and P < 0.1 are shown in light red for OR > 1 and light green for OR < 1.

statistically robust trend toward more MDS-associated mutations (70% vs. 27.3%, OR 6.22, P = 0.086)
and MDS transformation (33.3% vs. 0%, OR 12.18, P = 0.093).
Age-related differences were strongly associated with presence of HPA. Adult-onset HPA patients had
more MDS-associated mutations (70% vs. 6.3%, OR 35, P < 0.001), cytogenetic abnormalities (50% vs.
5.9%, OR 16, P = 0.004), and MDS transformation (33.3% vs. 2.7%, OR 18, P = 0.010) compared with
pediatric-onset HPA patients. However, no significant age-related differences in MDS-associated evolution
were seen in patients with LPA.
At an individual allele level, adult-onset patients with HLA-B*14:02 had more MDS transformation (4 of 6, 66.7%) compared with adult-onset patients lacking HLA-B*14:02 (0 of 17, 0%, P =
0.002). Pediatric-onset patients with HLA-B*14:02 did not differ in MDS rate from patients lacking
HLA-B*14:02 (1 of 10, 10% vs. 1 of 87, 1.1%, P = 0.197) (albeit with the limitation of statistical power
given the low rate of pediatric MDS). Other alleles in the HPA group were insufficiently represented
in the NAPAAC cohort and did not allow for statistical power to analyze contributions of individual
alleles other than HLA-B*14:02.
HLA risk alleles do not affect AA alloHSCT outcomes. Graft failure is a feared complication of
alloHSCT in AA that occurs in up to 21% of AA alloHSCT recipients and in many cases is thought
to be mediated by an immunologic rejection of the HLA-matched graft by the patient’s T cells (30).
The higher frequency of immunologic graft rejection after alloHSCT in AA versus other diseases is
thought to be due to the preexisting T cell clone that targets HSPCs via HLA allele-restricted immunity
and that was responsible for driving initiation of AA. We thus sought to determine the effect of HPA
on frequency of graft failure and other relevant alloHSCT outcomes in an independent CIBMTR-outcomes cohort of 484 patients with AA who received an HLA-matched bone marrow graft (MRD or
8/8 MUD) (Supplemental Figure 4). Within this cohort, 34.3% (n = 166) had HPA, 79% of patients
previously had IST, 84% received alloHSCT from MUD, 89% received bone marrow grafts, 98% of
patients received nonmyeloablative regimens, and 70% received methotrexate and calcineurin inhibitor–based GVHD prophylaxis. HPA and LPA groups were well balanced, with the exception of more
recent transplants in the HPA group (Supplemental Table 10).
In the whole cohort, 1-year incidence of graft failure was 8.6% and 1-year overall survival (OS) was 86.9%.
After adjusting for significant covariates, there was no significant association between HPA carrier status and
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Figure 6. Comparisons of peptide-binding pocket residues and peptide repertoire motifs for AA risk and non-risk HLA alleles. (A) A high-resolution
crystal structure of HLA-B*14:02 (Protein Data Bank 3BVN; ref. 50), highlighting the location of previously established key residues (shown in yellow,
listed in B) within the peptide-binding groove, which determines peptide-binding specificity for each allele. (B and C) Alignment of key residues in the
HLA-binding groove showing peptide-binding pocket structure for groups of AA risk (B) and non-risk (C) alleles. Amino acids in alignment are listed using a
single-letter amino acid code and colored using the “Rasmol/shapely” color scheme according to amino acid properties: D, E — bright red; C, M — bright yellow; K, R — medium blue; S, T — orange; F, Y — dark blue; Q, N — cyan, G — light gray; L, V, I — green; A — dark gray; W — pink; H — pale blue. Three risk alleles
(HLA-B*55:02, HLA-B*54:01, and HLA-A*02:05), previously reported by other groups (11, 13, 15, 16, that share peptide-binding pocket structures with our
identified risk alleles are included in the analysis. (D and E) Shown are the logo plots of 9–amino acid HLA class I peptides plotted based on experimentally
obtained immunopeptidome data from HLA class I monoallelic cell lines (23). Logo plots for identified risk alleles with available immunopeptidome data
are shown in D and for non-risk alleles in E. Alleles are grouped by HLA supertype assignment and peptide-binding pocket identify. Risk and non-risk (NR)
supermotifs characterizing groups of alleles based on peptide-binding pocket identity are labeled. Of note, non-risk alleles HLA-B*44:02 and HLA-B*44:03
share the B44 supermotif with HLA-B*40:02 but have distinct requirements for aromatic and polar residues at the C-terminus.

patient outcomes (Table 3 and Supplemental Table 11). HPA patients had similar incidence of graft failure, OS,
acute or chronic GVHD, and neutrophil and platelet engraftment. Consistent with prior studies, OS was worse
in older patients, those with poor performance status, and patients receiving unrelated donor grafts (31–33).
To assess whether presence of shared risk alleles between haploidentical donors and patients adversely affects outcomes of haploidentical alloHSCT — e.g., by allowing putative AA autoantigen(s) in the
haploidentical graft to be presented by a shared risk allele and potentiating graft rejection — we compared
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040

10

RESEARCH ARTICLE

Figure 7. Association analysis of risk and non-risk HLA alleles with AA in the NMDP cohort. Shown are statistically
significant associations of between risk and non-risk HLA-A and -B alleles in different racial and ethnic groups, using
the higher stringency multiple-testing adjustment FDR Padj < 0.05 (A) and unadjusted P < 0.05 (B). ORs with 95% CI are
shown for individual alleles, color-coded for different ethnicities (Asian & Pacific Islander — pink downward triangles;
Black — red squares; Hispanic — blue upward triangles; Native American — black diamonds; White — green circles). All
details for association study analysis for the risk and non-risk HLA alleles for each of the ethnic groups, including the
numbers of patients with AA and controls with each allele; the frequencies of alleles in patients and controls; the ORs;
the 95% CIs; and the P values, including P values adjusted for multiple testing, are included in Supplemental Table 5.

outcomes of 29 patients who received haploidentical grafts from donors matched (HPA-concordant, n =
15) or mismatched (HPA-discordant, n = 14) for HPA of the recipient (CIBMTR-haplo cohort). There
were no significant differences in 1- and 2-year graft failure rates or platelet and neutrophil engraftment
based on donor risk allele status (Supplemental Tables 12 and 13). Similarly, no differences in outcomes
were seen when all 19 risk alleles were considered (Supplemental Tables 14 and 15).

Discussion
Our results, based on several large independent cohorts of AA patients, provide a comprehensive
analysis of the spectrum of HLA class I contributions to AA pathogenesis. Using a combination of
frequency of HLA mutations, peptide-binding specificities, and association with AA, we identified 19
AA risk alleles. Additionally, we identified 12 non-risk (protective) alleles and established a pathogenicity stratification for HLA class I alleles in AA. Our results define AA pathogenicity for HLA-A and
HLA-B alleles for >60%–85% of individuals in diverse populations and demonstrate HLA drivers of
AA in different races and ethnicities. Our study demonstrates that while individual HLA-A and HLA-B
alleles convey distinct risks of developing AA, once AA occurs, allele-specific patterns of autoimmune
recognition do not appear to significantly alter immunologic outcomes following IST or alloHSCT.
However, in the non-alloHSCT setting, HPA, such as HLA-B*14:02, increase clonal evolution. In pediatric-onset AA, HPA increase the risk of somatic HLA loss, whereas in adult-onset AA, HPA are also
associated with an increased risk of MDS-associated clonal evolution.
Our findings shed light on autoimmunity in AA by showing that there are several groups of AA risk
alleles characterized by distinct peptide-binding motifs, with each group likely presenting a distinct autopeptide or its close variations — presumably derived from shared AA autoantigen(s). High-risk alleles
JCI Insight 2022;7(22):e163040 https://doi.org/10.1172/jci.insight.163040
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Figure 8. Risk allele contributions to AA and their relative prevalence across populations. Radar plots showing the OR for association with AA
(line plot) and population prevalence (shaded area plot) for 19 HLA class I risk alleles in Asian and Pacific Islander (A), Black (B), Hispanic (C), Native
American (D), and White (E) populations. Alleles are listed around the perimeter of the circle in alphanumeric order, highlighted by red outline for FDR
Padj < 0.05 from Figure 7A and black outline for P < 0.05 in Figure 7B. The line plots show the relative contributions of individual alleles as reflected by
the OR of the association with AA; circular grid lines mark OR intervals of 1 (with the inner circle, where OR = 1, indicates the threshold outside of which
there is a positive association with AA). Several rare alleles had OR > 3, which were allowed to be off scale to enable a clear depiction of smaller but
significant associations. The relative prevalence of alleles is shown by shaded area plots; these are depicted schematically using a different (logarithmic) scale to facilitate visualization of both very common and very rare alleles.
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Figure 9. Comparisons of risk allele contributions to AA and their relative prevalence across populations. (A) Black, Hispanic, and White. (B) Asian and
White. Alleles are listed around the perimeter of the circle in alphanumeric order, highlighted by red outline for FDR Padj < 0.05 from Figure 7A and black
outline for P value < 0.05 in Figure 7B. The line plots show the relative contributions of individual alleles as reflected by the OR of the association with
AA; circular grid lines mark OR intervals of 1 (with the inner circle, where OR = 1, indicating the threshold outside of which there is a positive association
with AA). Several rare alleles had OR > 3, which were allowed to be off scale to enable a clear depiction of smaller but significant associations. The relative
prevalence of alleles is shown by shaded area plots; these are depicted schematically using a different (logarithmic) scale to facilitate visualization of both
very common and very rare alleles.

differ in their peptide repertoires from lower risk alleles, suggesting that differences in allele pathogenicity in AA are due to autopeptide specificity. We speculate that this could occur if certain autopeptides
contribute less to thymic negative selection of autoreactive T cells or are similar to viral epitopes causing
cross-reactivity. While HPA increase the risk of developing AA, our results suggest that once a break in
immune tolerance occurs and autoimmunity ensues, AA severity and responses to IST and alloHSCT do
not differ based on the type of risk allele responsible for AA autoantigen presentation.
Importantly, our study shows that patients with HPA have an increased risk of clonal evolution, which
is particularly high in adult-onset HPA patients. The significantly higher incidence (Table 1 and Table 2) of
MDS-associated abnormalities in adult compared with pediatric patients could be explained by preexisting
age-related clonal hematopoiesis in adults (34, 35). Additionally, we speculate that HPA may have a more
insidious role in AA by sustaining occult autoimmune attack on HSPCs over time and may contribute to
a longer “prodromal” period of occult autoimmune attack preceding AA diagnosis in some adult-onset
patients (36). We also speculate that ethnicity-based differences in AA risk alleles and allele groups (e.g.,
HLA-B*14:02, an allele most closely linked to adverse clonal evolution, which is nearly absent in East Asia)
likely contribute to population-based differences in AA incidence and may also contribute to differences in
rates of post-AA secondary MDS.
Our study has limitations. Our HLA NGS analysis can reliably identify somatic mutations down to
approximately 2% variant allele fraction. While we may have missed very tiny clones, we increased the specificity of detecting pathogenic mutations in true risk alleles by focusing on more significant clonal expansions of
HLA-lacking cells. While we could not estimate AA pathogenicity for rare HLA alleles, our study included a
diverse cohort of 505 patients with AA, allowing us to estimate pathogenicity for alleles in >60% of Asian and
Black, >70% of Hispanic and Native American, and >85% of White North Americans. Our outcomes analysis
may have failed to detect small differences in relapse, graft failure, and pediatric MDS due to insufficient cohort
size. However, we evaluated 2 large independent multi-institutional cohorts, performing the first analysis to
our knowledge of the role of HPA in alloHSCT outcomes in AA. Finally, while the number of patients with
MDS-associated evolution was small, particularly among those with adult-onset AA, the effects of HPA and
HLA-B*14:02 were statistically robust, were in agreement with our previous observations (10), and were supported by recent findings for HLA-B*14:02 from an independent cohort of patients from the NIH (15).
In conclusion, our study provides insights into the immune pathogenesis of AA, which will inform
future efforts of autoantigen identification in AA and could be adapted to other autoimmune diseases.
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Table 1. The effect of HPA on clinical outcomes of patients with AA (overall cohort) treated with IST
Clinical outcome

Response to IST
at 6 months

Relapse
6pLOH
PNH
MDS-associated
mutations
Cytogenetic
abnormalities
MDS

NR, n (%)
OR (CR+PR)
CR, n (%)
PR, n (%)
NE, n
Yes, n (%)
No, n (%)
NE, n
Yes, n (%)
No, n (%)
Yes, n (%)
No, n (%)
NE, n
Yes, n (%)
No, n (%)
NE, n
Yes, n (%)
No, n (%)
NE, n
Yes, n (%)
No, n (%)
NE, n

All (n = 156)

HPA (n = 62)

No HPA (n = 94)

20 (18.2%)
89 (80.9%)
38 (34.9%)
51 (46.8%)
47
36 (33.6%)
71 (66.4%)
49
18
138
67
65
24
17
84
55
10
96
50
6
115
35

10 (23.3%)
32 (74.4%)
15 (34.9%)
17 (40.5%)
20
10 (24.4%)
31 (75.6%)
21
12 (19.4%)
50 (80.7%)
24 (44.4%)
30 (55.6%)
8
9 (21.4%)
33 (78.6%)
20
7 (15.9%)
37 (84.1%)
18
5 (10.2%)
44 (89.8%)
13

10 (14.9%)
57 (85.1%)
23 (35.9%)
34 (53.1%)
27
26 (39.4%)
40 (60.6%)
28
6 (6.4%)
88 (93.6%)
43 (55.1%)
35 (44.9%)
16
8 (13.6%)
51 (86.4%)
35
3 (4.8%)
59 (95.2%)
32
1 (1.4%)
71 (98.6%)
22

OddsR (95% CI)

P

1.78
(0.70–4.44)

0.310

0.50
(0.20–1.13)

0.142

3.52
(1.24–9.92)

0.020

0.65
(0.32–1.30)

0.228

1.73
(0.62–5.18)

0.419

3.67
(0.92–13.72)

0.089

8.07
(1.03–96.18)

0.039

Odds ratio calculation for overall response (CR+PR) versus no response. Odds ratio and P value for significant associations with P < 0.05 are shown in bold,
of which those pertaining to clonal evolution are highlighted in red font. P value calculations performed with Fisher’s exact test. HPA, higher pathogenicity
alleles: HLA-A*33:03, B*13:02, B*14:01, B*14:02, B*27:05, B*40:02, B*41:02, B*49:01, or B*56:01; IST, immunosuppressive therapy; OddsR, odds ratio;
NR, no response; OR, overall response; CR, complete response; PR, partial response; NE, not evaluable: no available data or no IST (e.g., due to frontline
transplant); MDS, myelodysplastic syndrome; 6pLOH, chromosome arm 6p loss of heterozygosity.

Increased MDS-associated clonal evolution in adult-onset AA patients with HPA should be confirmed in
larger studies, but our results suggest that this group of patients may benefit from surveillance for long-term
MDS-associated clonal evolution after IST.

Methods
Methods are summarized in Figure 1, with details provided in Supplemental Methods.

Patients with AA
AA was diagnosed using standard criteria (37–40). Severity of AA was defined according to Camitta Criteria (41). The HLA risk allele discovery cohort was assembled from 2 independent cohorts of
patients with AA (Figure 1 and Supplemental Table 1). The 156 patients in the NAPAAC cohort included 98 AA patients of any AA severity from the Penn-CHOP Bone Marrow Failure Syndrome cohort (66
of whom were included in our previous study, ref. 10) and 58 patients recruited from other NAPAAC
centers. Because the 156-patient NAPAAC cohort was used for both risk allele discovery and subsequent clinical outcomes analysis, it included consecutively enrolled patients. The second (CIBMTR-discovery) cohort consisted of 349 patients with AA participating in the CIBMTR research database.
Patients for the CIBMTR-discovery cohort were selected to maximize the probability of identifying
previously undiscovered risk alleles by analyzing patients who did not carry the 2 already known, most
common AA risk alleles, HLA-B*14:02 and HLA-B*40:02 (9, 10). This preselection of patients for the
CIBMTR-discovery cohort did not bias the subsequent HLA association or alloHSCT outcomes analysis, because those analyses were performed in separate, independent cohorts of patients (see Figure
1). The alloHSCT outcomes analysis was performed using an independent CIBMTR-outcomes cohort
of 484 CIBMTR AA patients who received an MRD or 8/8 MUD alloHSCT between 1988 and 2018.
A separate cohort of NMDP patients, identified based on patient donor search activity of the NMDP
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Table 2. The effect of HPA on clinical outcomes of patients with AA (pediatric- versus adult-onset cohort) treated with IST
Pediatric-onset AA
Clinical outcome

NR, n (%)
OR
Response to IST (CR+PR)
at 6 months CR, n (%)
PR, n (%)
NE, n
Yes, n (%)
No, n (%)
Relapse
NE, n
Yes, n (%)
6pLOH
No, n (%)
Yes, n (%)
No, n (%)
PNH
NE, n
Yes, n (%)
MDS-associated
No, n (%)
mutations
NE, n
Yes, n (%)
Cytogenetic
No, n (%)
abnormalities
NE, n
Yes, n (%)
No, n (%)
MDS
NE, n

Pediatric
total
(n = 121)
18 (20%)

HPA
(n = 47)

No HPA
(n = 74)

8 (25%)

10 (17.2%)

72 (80%)

24 (75%) 48 (82.8%)

33 (36.7%)
39 (43.3%)
31
27 (31.4%)
59 (68.6%)
35
15
106
52
55
14
7
73
41
5
82
2
96
23

13 (40.6%)
11 (34.4%)
15
8 (26.7%)
22 (73.3%)
17
10 (21.3%)
37 (78.7%)
16 (38.1%)
26 (61.9%)
5
2 (6.3%)
30 (93.8%)
15
2 (5.9%)
32 (94.1%)
34
1 (2.7%)
36 (97.3%)
10

OddsR (95%
CI)

1.60A
20 (34.5%) (0.53–4.39)
28 (48.3%)
16
19 (33.9%)
0.71
37 (66.1%)
(0.26–1.81)
18
5 (6.8%)
3.73
69 (93.2%) (1.23–10.26)
36 (55.4%)
0.50
29 (44.6%)
(0.23–1.10)
9
5 (10.4%)
0.57
43 (89.6%)
(0.11–3.02)
26
3 (5.7%)
1.04
50 (94.3%) (0.18–5.33)
21
13
1 (1.6%)
1.67
60 (98.4%)
(0.09–32.13)
13

Adult-onset AA

P

0.417

0.627
0.024
0.113

0.696

1.000

1.000

Adult
total
(n = 23)
2 (10.5%)

HPA
(n = 12)

No HPA
(n = 11)

2 (20%)

0 (0%)

17 (89.5%)

8 (80%)

9 (100%)

5 (26.3%)
12 (63.2%)
4
9 (42.9%)
12 (57.1%)
2
3
20
13
10
0
10
11
2
5
14
4
4
19
0

2 (20%)
6 (60%)
2
2 (18.2%)
9 (81.8%)
1
2 (16.7%)
10 (83.3%)
8 (66.7%)
4 (33.3%)
0
7 (70%)
3 (30%)
2
5 (50%)
5 (50%)
2
4 (33.3%)
8 (66.7%)
0

OddsR
(95% CI)

5.59
3 (33.3%) (0.43–inf)
6 (66.7%)
2
7 (70.0%)
0.10
3 (30.0%) (0.02–
0.85)
1
1 (9.1%)
2.00
10 (90.9%) (0.20–31.52)
5 (45.5%)
2.40
6 (54.5%)
(0.40–12.01)
0
3 (27.3%)
6.22
8 (72.7%)
(0.82–31.78)
0
0 (0%)
19.00
9 (100%)
(1.50–inf)
2
0 (0%)
12.18
11 (100%)
(0.90–inf)
0

P

0.474

0.030
1.000
0.414

0.086

0.033

0.093

Odds ratio calculation for overall response (CR+PR) versus no response. Odds ratios and P values for significant associations with P < 0.05 are shown
in bold; those pertaining to clonal evolution are highlighted in red font. HPA, higher pathogenicity alleles: HLA-A*33:03, B*13:02, B*14:01, B*14:02,
B*27:05, B*40:02, B*41:02, B*49:01, or B*56:01; IST, immunosuppressive therapy; OddsR, odds ratio; NR, no response; OR, overall response; CR, complete
response; PR, partial response; NE, not evaluable: no available data or no IST (e.g., due to frontline transplant); MDS, myelodysplastic syndrome; 6pLOH,
chromosome arm 6p loss of heterozygosity; inf, infinity.

registry, were used for HLA association analyses. In accordance with the American Academy of Pediatrics, pediatric-onset AA was defined as the diagnosis of AA up to the age of 21 years (42).

Somatic HLA loss
Somatic HLA loss was identified in the discovery cohort using a combination of targeted NGS of the
HLA-A, -B, and -C genes to identify somatic mutations and SNP-A genotyping to identify acquired
6pCN-LOH, performed on peripheral blood or bone marrow DNA, as described (10, 43). Every HLA
variant was manually curated in Integrative Genomics Viewer; most variants were additionally independently verified using Twin (Omixon) software (10, 43, 44). Due to limited quantities of hematopoietic cell DNA for some patients, 17 patients were only analyzed by HLA NGS but not SNP-A; in these
patients, acquired 6pCN-LOH was analyzed using read depth imbalance across the sequenced HLA-A,
-B, and -C alleles. A total of 14 patients were only analyzed for 6pCN-LOH by SNP-A but did not have
sufficient DNA quantity for HLA NGS.

Peptide-binding analyses
The amino acid residues comprising the peptide-binding pockets of HLA-A/B proteins, which determine HLA peptide repertoires, were previously established by crystallographic analyses (21, 45–48).
The residues considered to form the “B pocket” were 7, 9, 24, 34, 45, 63, 66, 67, 70, and 99, and
those for the “F pocket” were 74, 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147 (21).
The peptide-binding motifs for AA HLA risk and non-risk alleles were based on previously published,
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15

RESEARCH ARTICLE

Table 3. Univariate analysis of alloHSCT outcomes of patients with AA stratified by HLA risk allele pathogenicity group (CIBMTRoutcomes cohort)
Outcomes

Graft failure
1 year
2 year
Overall survival
100 days
6 months
1 year
Grade 2–4 acute GVHD
100 days
6 months
Chronic GVHD
6 months
1 year
Neutrophil engraftment
1 month
Platelet recovery
1 month
100 days

Patients with AA WITH higher pathogenicity HLA Patients with AA WITHOUT higher pathogenicity
risk alleles (N = 166)
HLA risk alleles (N = 318)

N
164

Probability, % (95% CI)

N
309

6.1 (3–10.3)
6.1 (3–10.3)
166

Probability, % (95% CI)
0.115
9.2 (6.2–12.7)
10 (6.9–13.7)

318
94.6 (90.6–97.5)
91.6 (86.9–95.3)
88.5 (83.2–92.9)

163

0.362
92.1 (88.9–94.8)
89.9 (86.4–93)
86.1 (82.1–89.7)

317
19.6 (13.9–26.1)
20.9 (15–27.5)

165

0.238
25.3 (20.7–30.2)
26 (21.3–30.9)

310
14.1 (9.2–19.9)
30.2 (23.4–37.5)

166

0.270
15.8 (11.9–20.1)
24.8 (20.1–29.8)

316
87.3 (81.8–92)

166

0.262
91.5 (88.1–94.3)

312
62.7 (55.1–69.9)
92.6 (87.8–96.2)

P value

0.193
54.8 (49.3–60.3)
89.9 (86.2–93)

Higher pathogenicity alleles: HLA-A*33:03, B*13:02, B*14:01, B*14:02, B*27:05, B*40:02, B*41:02, B*49:01, or B*56:01. GVHD, graft-versus-host disease.

experimentally obtained immunopeptidomes from HLA class I monoallelic cell lines (23). Peptides
eluted from cell lines expressing a single HLA class I allele were downloaded for each allele of interest
(23), except HLA-B*14:01, HLA-B*41:02, and HLA-B*50:02, for which immunopeptidome data were
not available. Logo plots were then generated using the ggseqlogo R package (49).

HLA pathogenicity rating
Relative pathogenicity of specific HLA class I alleles in AA was determined by the mutation frequency in
analyzed AA patients carrying those alleles. Mutation frequencies were compared by Fisher’s exact tests.

Statistics
HLA association. Association analysis of HLA class I alleles with AA was performed in 6,323 patients with
AA who searched the NMDP registry and presumed healthy controls (n = 31,057 to 50,000 per racial and
ethnic group, as shown in Figure 1 and Supplemental Table 4), randomly selected from the unrelated donor
registry after matching for sex, age, and ethnicity. The ORs and 95% CIs were calculated for each HLA
variant within each ethnic group. Multiple-testing adjustment was performed using the FDR method with
the adjusted P value at <5% FDR threshold considered significant (24).
Clinical outcomes. The effect of HPA on IST outcomes was evaluated in a retrospective 156-patient
NAPAAC cohort by comparing outcomes of patients with and without HPA using Fisher’s exact tests.
The effect of HPA on transplant outcomes was evaluated in the CIBMTR-outcomes cohort using multivariate Cox proportional hazards analysis adjusting for age, Karnofsky performance status, donor
type, and conditioning.
For all analyses, 2-tailed P values less than 0.05 were considered significant.

Study approval
Patients were recruited with Institutional Review Board approval of respective NAPAAC institutions. CIBMTR/NMDP studies were approved by NMDP IRB overseeing CIBMTR research protocols.
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